By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Opioids (narcotic analgesics) > Depodur > Morphine Liposomal Dosage
Opioids (narcotic analgesics)
https://themeditary.com/dosage-information/morphine-liposomal-dosage-2275.html

Morphine Liposomal Dosage

Drug Detail:Depodur (Morphine sulfate extended-release liposome injection)

Drug Class: Opioids (narcotic analgesics)

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Pain

Major Orthopedic Surgery of the Lower Extremity: 15 mg via lumbar epidural administration once prior to surgery

Lower Abdominal or Pelvic Surgery: 10 to 15 mg via lumbar epidural administration once prior to surgery

Maximum dose: 20 mg

Caesarian Section: 10 mg via lumbar epidural administration once after clamping of the umbilical cord

Comments:

  • Like all opioids, dosing requirements will vary and it is necessary to individualize dose taking into account patient's age, body mass, physical status, prior opioid experience, risk factors for respiratory depression, and concomitant medications.
  • This drug should not be administered to women for vaginal labor and delivery.

Use: For the treatment of pain following major surgery.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Dose Adjustments

Elderly and Debilitated Patients:

  • Carefully evaluate benefits and risks
  • Dose should generally be at the low end of the dosing range
  • May require monitoring for periods longer than 48 hours

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to active substance or any component of the product
  • Respiratory depression
  • Acute or severe bronchial asthma
  • Upper airway obstruction
  • Any contraindication that precludes an epidural injection
  • Paralytic ileus
  • Known head injury
  • Increased intracranial pressure
  • Circulatory shock

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule II

Dialysis

Data not available

Other Comments

Administration advice:

  • For lumbar epidural administration only; not intended for intrathecal, intravenous, or intramuscular administration
  • Do not use an in-line filter during administration
  • Proper needle or catheter placement into epidural space must be verified prior to injection; administration at the thoracic level or higher is not recommended because it has not been studied.
  • Once administered, no other medication should be administered into the epidural space for at least 48 hours

Storage requirements:
  • Protect from freezing; each vial has a freeze indicator that should be checked prior to administration. If the bulb of the freeze indicator changes from clear to pink or purple, the vial may have frozen and should not be used.
  • Store refrigerated (36F to 46F [2C to 8C]) in carton
  • Unopened intact vials may be held at room temperature for up to 30 days, after 30 days they should be discarded; these vials should not be returned to the refrigerator.

Reconstitution/preparation techniques:
  • May be administered undiluted or may be diluted to a total volume of up to 5 mL (dilute with preservative-free 0.9% normal saline)
  • Gently invert vials to re-suspend the particles immediately prior to withdrawal from the vial; avoid aggressive agitation.
  • Following withdrawal from the vial, may keep at room temperature (59F to 86F) for up to 4 hours prior to administration; do not heat-sterilize or gas-sterilize

Compatibility:
  • Do not mix with any other medication

General:
  • This drug should be administered under the direct supervision of a physician experienced in the technique of epidural administration; it should be administered in a setting with staff and equipment to manage severe respiratory depression; patients should be monitored for a minimum of 48 hours after dosing.

Monitoring:
  • Monitor for respiratory depression for a minimum of 48 hours after administration in a facility with staff and equipment to manage significant respiratory depression
  • Monitor for orthostatic hypotension during post-surgical ambulation, especially in patients with reduced circulating blood volume, impaired myocardial function, and those receiving concomitant sympatholytic drugs
Share this Article
Latest News
Medical News

Mental health: Low-calorie diets may increase depression

Jun 07, 2025
Psilocybin for IBS: Could altering the mind help alter the gut?
Colon cancer: Adding immunotherapy may halve death, recurrence rate
Colon cancer: Exercise as important as drugs in preventing recurrence
Alzheimer's: Common insomnia treatment may prevent brain damage
Cholesterol: Daily cup of beans may lower levels, improve heart health
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by